Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs – Business Wire (press release)
|
Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican's Immunotherapy Clinical Programs
Business Wire (press release) “With immunotherapies dominating the treatment landscape, we continually find that our technology can help our partners, such as Pelican, advance candidates for unmet medical needs including certain cancers,” said Yemi Onakunle, PhD, MBA, Selexis vice … |
